Secondary Logo

Institutional members access full text with Ovid®

Successful Haploidentical Stem Cell Transplant With Posttransplant Cyclophosphamide for Hemophagocytic Lymphohistiocytosis

Kohli, Shruti, MD*,†; Rastogi, Neha, DCH, DNB*,†; Nivargi, Sagar, DCH, DNB*,†; Thakkar, Dhwanee, MD, FNB*,†; Katewa, Satyendra, DCH, DNB*; Yadav, Satya P., DCH, DNB*,†

Journal of Pediatric Hematology/Oncology: April 2019 - Volume 41 - Issue 3 - p e158–e160
doi: 10.1097/MPH.0000000000001265
Online Articles: Clinical and Laboratory Observations

Allogeneic hematopoietic stem cell transplant (HSCT) has been known to be a curative therapy for patients with hemophagocytic lymphohistiocytosis (HLH) but donor availability is an issue. Haploidentical HSCT with posttransplant cyclophosphamide (PTCy) has been investigated as a feasible option for various malignant and nonmalignant conditions with reduced incidence of acute graft versus host disease (GVHD) and graft rejection. However, its use has not been described in children with HLH and here we describe 2 boys who underwent successful haploidentical HSCT with PTCy. None had acute GVHD and 1 had limited chronic GVHD. Both are alive and disease-free at follow-up of 912 and 239 days, respectively. Haploidentical HSCT with PTCy is a feasible option for children with HLH lacking a matched sibling donor.

*Pediatric Hematology Oncology and Bone Marrow Transplant Unit, Fortis Memorial Research Institute

Pediatric Hematology Oncology and Bone Marrow Transplant Unit, Cancer Institute, Medanta, The Medicity, Gurgaon, Haryana, India

The authors declare no conflict of interest.

Reprints: Satya P. Yadav, DCH, DNB, Pediatric Hematology Oncology and BMT Unit, Cancer Institute, Medanta The Medicity, Gurgaon, Haryana, India 122001 (e-mail:

Received August 11, 2017

Accepted June 24, 2018

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.